OR WAIT null SECS
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling
Heidi J. Einolf is director, modeling and simulation, pharmacokinetic sciences, Novartis.
Stephen D. Hall is senior research fellow, drug disposition, Eli Lilly and Co.
Tracy Williams is senior director ADME/Toxicology/PKPD, Eli Lilly and Co.
Aarti Patel is director, DMPK modeling, GlaxoSmithKline.
Christopher Gibson is distinguished scientist, Merck.
Nancy G.B. Agrawal is vice-president, pharmacokinetics, pharmacodynamics, and drug metabolism, Merck.
Jens Sydor is vice-president, DMPK, GlaxoSmithKline.
Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
Predictive sciences—built on improved computational capabilities and a deeper understanding of human physiology—are allowing researchers to perform human studies prior to, and sometimes in place of, human clinical trials in order to predict drug outcomes. Representatives of the Translational & ADME Sciences Leadership Group (TALG) in the IQ Consortium review the basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process.
Read this article in BioPharm International's Regulatory Sourcebook March 2021 eBook.
Article Details
BioPharm International
eBook: Regulatory Sourcebook
March 2021
Pages: 27–30
Citation
When referring to this article, please cite it as H. Einolf, et al., " Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling," BioPharm International Regulatory Sourcebook eBook (March 2021).
Related Content:
